Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1024687

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that there is no disparity in access to treatments for rare diseases between the UK and economically similar countries in Europe.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	202087
answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>The Government is committed to the safe and effective regulation of medicines in the United Kingdom; ensuring patients and the public have fast access to new, innovative medicines, including medicines for rare diseases.</p><p> </p><p>The agreement of an implementation period will ensure that access to medicines continues, and patient safety is maintained, in both the UK and European Union markets. Beyond that, the Political Declaration sets out a plan for a free trade area for goods, underpinned by deep regulatory co-operation, as well as a joint commitment to explore close cooperation with the European Medicines Agency.</p><p> </p><p>The Government also continues to prepare for the unlikely outcome that we leave the EU without any deal in March 2019. The Department has been engaging with all pharmaceutical companies that supply the United Kingdom with pharmacy or prescription-only medicines from, or via, the EU/European Economic Area, on their contingency plans in the event of a no deal EU exit.</p><p> </p><p>Whatever the exit scenario, we will continue to ensure that UK patients are able to access the best and most innovative medicines including medicines for rare diseases and that their safety is protected.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 18/12/2018 17:36:24 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4249 label Biography information for Anne Marie Morris

1024698

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Orphan Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he is taking steps to introduce a revised definition for ultra-orphan medicine.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	202090
answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>Currently, rare diseases are defined as conditions affecting no more than five in 10,000 people in the European Union. The new European Clinical Trial Regulation (Regulation (EU) No 536/2014) will introduce an ‘ultra-rare’ condition and states that clinical trials for the development of orphan medicinal products and those of medicines affecting no more than one person in 50,000 in the EU (ultra-rare diseases) should be fostered, and in such areas, a rapid yet in-depth assessment is of particular importance. The new clinical trials regulation is expected to be implemented in the EU in late 2020. The Government has confirmed that United Kingdom law will remain aligned with the parts of the new EU clinical trials Regulation that are within the UK’s control.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 20/12/2018 17:10:46 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4488 label Biography information for Martyn Day

1024700

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the UK remains a world leader for the treatment of rare diseases after the UK leaves the EU.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	202091
answer	answer is ministerial correction date of answer 20/12/2018 answer text <p>The Government is committed to the safe and effective regulation of medicines in the United Kingdom; ensuring patients and the public have fast access to new, innovative medicines, including medicines for rare diseases.</p><p> </p><p>The agreement of an implementation period will ensure that access to medicines continues, and patient safety is maintained, in both the UK and European Union markets. Beyond that, the Political Declaration sets out a plan for a free trade area for goods, underpinned by deep regulatory co-operation, as well as a joint commitment to explore close cooperation with the European Medicines Agency.</p><p> </p><p>The Government also continues to prepare for the unlikely outcome that we leave the EU without any deal in March 2019. The Department has been engaging with all pharmaceutical companies that supply the United Kingdom with pharmacy or prescription-only medicines from, or via, the EU/European Economic Area, on their contingency plans in the event of a no deal EU Exit.</p><p> </p><p>Whatever the exit scenario, we will work to ensure that the UK will remain a world leader for the treatment of rare diseases after the UK leaves the EU, that UK patients are able to access the best and most innovative medicines including medicines for rare diseases and that their safety is protected. The UK life sciences industry has much to offer in creating, developing, trialing and commercialising medicines that will benefit UK patients and strengthen the ability of the UK to compete internationally.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 20/12/2018 17:07:43 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4488 label Biography information for Martyn Day

1024731

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the briefing published by the Children's Commissioner entitled Children’s Mental Healthcare in England published November 2018, what steps his Department is taking to reduce waiting times for children with mental health problems.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	202100
answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>We have made an additional £1.4 billion available for children’s mental health service transformation and are on track to ensure that an additional 70,000 children and young people access community mental health services annually by 2020/21.</p><p> </p><p>We have introduced two waiting time standards for children and young people and are on track to meet both of these standards. The first aims for 95% of children (up to 19 years old) with eating disorders to receive treatment within a week for urgent cases and four weeks for routine cases. The second aims for 50% of patients of all ages experiencing a first episode of psychosis to receive treatment within two weeks of referral.</p><p> </p><p>Our Children and Young People’s Green Paper, jointly published with the Department for Education, sets out how we plan to go further. We are piloting a four-week waiting time to improve access to services and are introducing new mental health support teams. Trailblazer sites, where we plan to test our Green Paper proposals, will be announced shortly.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 18/12/2018 14:36:32 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4243 label Biography information for Dan Jarvis

1024791

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Eating Disorders
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 10 December 2018 to Question 197605, whether the long-term plan for the NHS will address regional variations in access to specialist support for adults with eating disorders.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	202083
answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>Mental health will be a core part of the National Health Service long-term plan, including building on the improvements in providing access to good mental health services. The NHS long-term plan is currently in development and will be published shortly by NHS England.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 18/12/2018 14:37:26 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1439 label Biography information for Norman Lamb

1023898

registered interest
date	12/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood: Contamination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what types of support the NHS Business Services Authority provides to victims and family members of those affected by the contaminated blood scandal; and whether that support includes (a) bookable appointments, (b) face-to-face support and (c) telephone support.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	201686
answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>Information on support available to beneficiaries of the England Infected Blood Support Scheme (EIBSS), administered by NHS Business Services Authority, is available on the EIBSS website at the following link:</p><p> </p><p><a href="https://www.nhsbsa.nhs.uk/england-infected-blood-support-scheme" target="_blank">https://www.nhsbsa.nhs.uk/england-infected-blood-support-scheme</a></p><p> </p><p>EIBSS does not provide beneficiaries with bookable appointments or face to face support. However, beneficiaries can obtain advice from the EIBSS’ telephone service where information on all support available can be obtained.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 18/12/2018 14:08:49 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4523 label Biography information for Catherine West

1023902

registered interest
date	12/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 13 September 2018 to Question 170818 on Health: Children, what the planned publication date is for the Social Care Policy Research Programme review of the effectiveness of interventions for children and young people aged 3-18 years who have experienced adverse childhood experiences.
tabling member constituency	Lewisham, Deptford
tabling member printed	Vicky Foxcroft
uin	201687
answer	answer is ministerial correction date of answer 17/12/2018 answer text <p>As set out in the answer to Question 170818, the review is expected to deliver its report to the Department by the end of the year. It will be published in due course, following peer review.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 17/12/2018 14:47:09 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4491 label Biography information for Vicky Foxcroft

1023927

registered interest
date	12/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Endometriosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many women have a diagnosis of endometriosis.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	201631
answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>The information is not held in the format requested.</p><p> </p><p>The Hospital Episode Statistics database records a count of 21,777 finished consultant episodes with a primary diagnosis of endometriosis in the financial year 2017-18.</p><p> </p><p>This figure does not necessarily represent the number of different patients, as a person may have more than one episode of care within the same stay in hospital or in different stays in the same year.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 18/12/2018 14:07:26 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4131 label Biography information for Jim Shannon

1023974

registered interest
date	12/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Post-traumatic Stress Disorder
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what information his Department holds on average waiting times for access to psychological therapies for patients with post-traumatic stress disorder in (a) Birmingham, (b) the West Midlands and (c) England.
tabling member constituency	Birmingham, Northfield
tabling member printed	Richard Burden
uin	201564
answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>The information requested is attached. It is taken from the Improving Access to Psychological Therapies (IAPT) dataset held by NHS Digital.</p><p> </p><p>The data shows that waiting times for IAPT services for people with post-traumatic stress disorder are decreasing both nationally and in West Midlands clinical commissioning groups.</p><p> </p><p>Improving Access to Psychological Therapies (IAPT) is a National Health Service programme that offers a range of National Institute for Health and Care Excellence-approved therapies for treating people with depression or anxiety.</p><p> </p><p>All historical IAPT publications, including annual data, are available at the following link:</p><p> </p><p><a href="http://digital.nhs.uk/iaptreports" target="_blank">http://www.digital.nhs.uk/iaptreports</a></p><p> </p><p>Further information about the IAPT dataset is available at the following link:</p><p> </p><p><a href="http://digital.nhs.uk/iapt" target="_blank">http://www.digital.nhs.uk/iapt</a></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 201573 question first answered 18/12/2018 14:27:57 answering member 4065 label Biography information for Dame Jackie Doyle-Price attachment 1 file name Data PQ201564 and PQ201573 (002).xlsx title PQ201564,PQ201573 attached data
tabling member	301 label Biography information for Richard Burden

1023975

registered interest
date	12/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Post-traumatic Stress Disorder
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of trends in waiting times for access to psychological therapies for people with post-traumatic stress disorder in (a) Birmingham and (b) England.
tabling member constituency	Birmingham, Northfield
tabling member printed	Richard Burden
uin	201573
answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>The information requested is attached. It is taken from the Improving Access to Psychological Therapies (IAPT) dataset held by NHS Digital.</p><p> </p><p>The data shows that waiting times for IAPT services for people with post-traumatic stress disorder are decreasing both nationally and in West Midlands clinical commissioning groups.</p><p> </p><p>Improving Access to Psychological Therapies (IAPT) is a National Health Service programme that offers a range of National Institute for Health and Care Excellence-approved therapies for treating people with depression or anxiety.</p><p> </p><p>All historical IAPT publications, including annual data, are available at the following link:</p><p> </p><p><a href="http://digital.nhs.uk/iaptreports" target="_blank">http://www.digital.nhs.uk/iaptreports</a></p><p> </p><p>Further information about the IAPT dataset is available at the following link:</p><p> </p><p><a href="http://digital.nhs.uk/iapt" target="_blank">http://www.digital.nhs.uk/iapt</a></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 201564 question first answered 18/12/2018 14:27:57 answering member 4065 label Biography information for Dame Jackie Doyle-Price attachment 1 file name Data PQ201564 and PQ201573 (002).xlsx title PQ201564,PQ201573 attached data
tabling member	301 label Biography information for Richard Burden